Topics and Cases - Propecia
Propecia is a specific type of 5-alpha reductase inhibitor. It inhibits the enzyme responsible for regulating conversion of testosterone to dihydrotestosterone (DHT). By reducing DHT levels in the scalp, finasteride decreases DHT's effects on the hair follicles, reversing the process of hair loss. Propecia is a brand name for the drug known as finasteride.
In the last year, Propecia has been shown in various studies and through a FDA warning to be associated with prostate cancer, sexual dysfunction, and reduced sexual desire.
Facts about Propecia:
- In March 2011, George Washington University professor Michael Irwig released a study published in the Journal of Sexual Medicine which reveals that Propecia can cause persistent sexual dysfunction, including low sexual desire, erectile dysfunction and problems with orgasms.
- Irwig’s study showed that 94% of subjects developed low libido, 92% developed erectile dysfunction and decreased arousal, and 69% developed problems with achieving orgasm.
- In June 2011, the FDA issued a warning that men taking finasteride may face a higher risk of developing high-grade prostate cancer.
- As a result, Merck changed the labeling for Propecia to include a warning for increased risk of high-grade prostate cancer.
- In August 2011, the Canadian Health Agency stated that male breast cancer had been reported in a small number of patients worldwide with both the 1 mg and 5 mg formulations of finasteride; though most have been associated with the 5mg formulation know as “Proscar.”
Litigation News:
- In October, 2011, Plaintiffs petitioned the New Jersey Supreme Court for mass tort designation and requested all cases filed in New Jersey state courts be consolidated and assigned to Judge Carol Higbee.
- In December, 2011, the attorneys at JMCC MEDIA filed a petition with the Judicial Panel on Multi-District Litigation seeking consolidation of all federal lawsuits alleging injury as a result of Propecia ingestion.